Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment

被引:15
|
作者
Zhou, Zhengyuan [1 ]
Meshaw, Rebecca [1 ]
Zalutsky, Michael R. [1 ]
Vaidyanathan, Ganesan [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
single-domain antibody fragment; site-specific labeling; immuno-PET; click chemistry; HER2; HER2 RECEPTOR EXPRESSION; N-SUCCINIMIDYL; NANOBODY;
D O I
10.2967/jnumed.120.261446
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Single-domain antibody fragments (sdAbs) are promising vectors for immuno-PET; however, better methods for labeling sdAbs with F-18 are needed. Herein, we evaluate a site-specific strategy using an F-18 residualizing motif and the anti-epidermal growth factor receptor 2 (HER2) sdAb 5F7 bearing an engineered C-terminal GGC tail (5F7GGC). Methods: 5F7GGC was site-specifically attached with a tetrazine-bearing agent via thiol-maleimide reaction. The resultant conjugate was labeled with F-18 by inverse electron demand Diels-Alder cycloaddition with a trans-cyclooctene attached to 6-F-18-fluoronicotinoyl moiety via a renal brush border enzyme-cleavable linker and a PEG4 chain (F-18-5F7GGC). For comparisons, 5F7 sdAb was labeled using the prototypical residualizing agent, N-succinimidyl 3-(guanidinomethyl)5-I-125-iodobenzoate (iso-I-125-SGMIB). The 2 labeled sdAbs were compared in paired-label studies performed in the HER2-expressing BT474M1 breast carcinoma cell line and athymic mice bearing BT474M1 subcutaneous xenografts. Small-animal PET/CT imaging after administration of F-18-5F7GGC in the above mouse model was also performed. Results: F-18-5F7GGC was synthesized in an overall radiochemical yield of 8.9% +/- 3.2% with retention of HER2 binding affinity and immunoreactivity. The total cell-associated and intracellular activity for F-18-5F7GGC was similar to that for coincubated iso-(125)ISGMIB-5F7. Likewise, the uptake of F-18-5F7GGC in BT474M1 xenografts in mice was similar to that for iso-I-125-SGMIB-5F7; however, F-18-5F7GGC exhibited significantly more rapid clearance from the kidney. Small-animal PET/CT imaging confirmed high uptake and retention in the tumor with very little background activity at 3 h except in the bladder. Conclusion: This site-specific and residualizing 18F-labeling strategy could facilitate clinical translation of 5F7 anti-HER2 sdAb as well as other sdAbs for immuno-PET.
引用
收藏
页码:1624 / 1630
页数:7
相关论文
共 36 条
  • [31] ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers
    Skidmore, Lillian
    Sakamuri, Sukumar
    Knudsen, Nick A.
    Hewet, Amha Gebre
    Milutinovic, Snezana
    Barkho, Wisam
    Biroc, Sandra Lyn
    Kirtley, Jessica
    Marsden, Robin
    Storey, Kristine
    Lopez, Ianina
    Yu, Wayne
    Fang, Shiao-Yan
    Yao, Sulan
    Gu, Yi
    Tian, Feng
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (09) : 1833 - 1843
  • [32] Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F] fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate
    Zhou, Zhengyuan
    McDougald, Darryl
    Meshaw, Rebecca
    Balyasnikova, Irina
    Zalutsky, Michael R.
    Vaidyanathan, Ganesan
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 100 : 24 - 35
  • [33] Fluorine-18 labeling of a single domain antibody fragment with 2,5-dioxopyrrolidin-1-yl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate, an alternative residualizing prosthetic agent.
    Zhou, Zhengyuan
    McDougald, Darryl
    Devoogdt, Nick
    Zalutsky, Michael
    Vaidyanathan, Ganesan
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S484 - S486
  • [34] Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios
    Zhou, Zhengyuan
    McDougald, Darryl
    Devoogdt, Nick
    Zalutsky, Michael R.
    Vaidyanathan, Ganesan
    MOLECULAR PHARMACEUTICS, 2019, 16 (01) : 214 - 226
  • [35] Fluorine-18 labeling of an anti-HER2 sdAb with 6-fluoronicotinyl moiety via the inverse electron-demand Diels-Alder reaction (IEDDAR) including a renal brush border enzyme-cleavable linker
    Zhou, Zhengyuan
    Zalutsky, Michael
    Vaidyanathan, Ganesan
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S480 - S482
  • [36] 18F-labeling of an anti-HER2 sdAb with a renal brush border enzyme-cleavable linker-containing prosthetic agent via a trans-cyclooctene (TCO)-terazine (Tz) inverse electron-demand Diels-Alder reaction (IEDDAR) for reduced renal uptake
    Zhou, Zhengyuan
    Devoogdt, Nick
    Zalutsky, Michael
    Vaidyanathan, Ganesan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59